Evidence map›Paper›PMID 37108756›Full record

ReviewInternational journal of molecular sciences2023

Colorectal Cancer Chemoprevention: A Dream Coming True?

Martina Lepore Signorile, Valentina Grossi, Candida Fasano, Cristiano Simone

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Cancer prevention: past challenges and future directions.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025
    Review
  6. Chemopreventive strategies for sporadic colorectal cancer: a narrative review.Translational gastroenterology and hepatology · 2025
    Review
  7. Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050?Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Martina Lepore SignorileMedical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Valentina GrossiMedical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Candida FasanoMedical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Cristiano SimoneMedical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Gastroenterology Hospital "Saverio de Bellis" · IT

Funding

Italian Association for Cancer Research ID26678Italian Association for Cancer Research IG-23794Italian Ministry of Health ricerca corrente 2021-2023Italian Ministry of Health Ricerca corrente 2022-2024Italian Ministry of Health Ricerca corrente 2023-2025
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the deadliest forms of cancer worldwide. CRC development occurs mainly through the adenoma-carcinoma sequence, which can last decades, giving the opportunity for primary prevention and early detection. CRC prevention involves different approaches, ranging from fecal occult blood testing and colonoscopy screening to chemoprevention. In this review, we discuss the main findings gathered in the field of CRC chemoprevention, focusing on different target populations and on various precancerous lesions that can be used as efficacy evaluation endpoints for chemoprevention. The ideal chemopreventive agent should be well tolerated and easy to administer, with low side effects. Moreover, it should be readily available at a low cost. These properties are crucial because these compounds are meant to be used for a long time in populations with different CRC risk profiles. Several agents have been investigated so far, some of which are currently used in clinical practice. However, further investigation is needed to devise a comprehensive and effective chemoprevention strategy for CRC.

Indexed as

AdenomaColorectal NeoplasmsChemopreventionColonoscopyEarly Detection of CancerHumanschemopreventioncolorectal cancerprecancerous lesionstarget populations

Identifiers

PMID37108756
PMCPMC10140862
OpenAlexW4366775232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.